Scios Final Analysis Of Natrecor Trial Finds Two Additional Deaths
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson subsidiary maintains the additional deaths have “no impact on overall risk/benefit profile” of the heart failure therapy.